The extensive studies reported in these and other papers, utilizing multiple in-depth in vivo models, provided solid positive preclinical data to warrant the initiation of Phase 1 clinical trials in 2014, of which a Phase 1 safety trial with SLC-0111 (as a monotherapeutic agent), has been completed [177] and a Phase 1b trial is currently underway to evaluate SLC-0111 in combination with gemcitabine in metastatic pancreatic cancer patients whose tumors are CA IX positive (ClinicalTrials.gov Identifier: NCT03450018). Here, CCL21 is linked to pancreatic neoplasm.